Optellum announces agreement with Bristol Myers Squibb to leverage AI to boost early lung cancer diagnosis
Oxford, UK, and Houston, TX, USA, April, 15, 2025: Optellum, a global leader in AI-driven clinical decision support for early lung cancer diagnosis, has entered an agreement with Bristol Myers Squibb (NYSE: BMY), to leverage AI in early diagnosis and …